SG11201510601TA - Antibody formulations and methods - Google Patents
Antibody formulations and methodsInfo
- Publication number
- SG11201510601TA SG11201510601TA SG11201510601TA SG11201510601TA SG11201510601TA SG 11201510601T A SG11201510601T A SG 11201510601TA SG 11201510601T A SG11201510601T A SG 11201510601TA SG 11201510601T A SG11201510601T A SG 11201510601TA SG 11201510601T A SG11201510601T A SG 11201510601TA
- Authority
- SG
- Singapore
- Prior art keywords
- methods
- antibody formulations
- antibody
- formulations
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Analytical Chemistry (AREA)
- Inorganic Chemistry (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361843011P | 2013-07-04 | 2013-07-04 | |
US201461979886P | 2014-04-15 | 2014-04-15 | |
PCT/IB2014/062806 WO2015001504A2 (en) | 2013-07-04 | 2014-07-03 | Antibody formulations and methods |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201510601TA true SG11201510601TA (en) | 2016-01-28 |
Family
ID=51355583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201510601TA SG11201510601TA (en) | 2013-07-04 | 2014-07-03 | Antibody formulations and methods |
Country Status (18)
Country | Link |
---|---|
US (2) | US10513555B2 (en) |
EP (2) | EP3016677B1 (en) |
JP (3) | JP6404338B2 (en) |
KR (1) | KR20160030247A (en) |
CN (1) | CN105492019B (en) |
AU (1) | AU2014285719A1 (en) |
CA (1) | CA2917097C (en) |
CL (1) | CL2015003801A1 (en) |
CU (2) | CU20170039A7 (en) |
ES (1) | ES2704440T3 (en) |
HK (1) | HK1223544A1 (en) |
IL (1) | IL243425A0 (en) |
MX (1) | MX2016000201A (en) |
PE (1) | PE20160868A1 (en) |
PH (1) | PH12015502788A1 (en) |
RU (1) | RU2016103079A (en) |
SG (1) | SG11201510601TA (en) |
WO (1) | WO2015001504A2 (en) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA116194C2 (en) | 2011-10-28 | 2018-02-26 | Протена Біосаєнсиз Лімітед | ANTIBODY THAT SPECIFICALLY Binds to HUMAN ALPHA SYNUCLEIN |
ES2749457T3 (en) | 2012-01-27 | 2020-03-20 | Prothena Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
UA118441C2 (en) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Antibodies recognizing alpha-synuclein |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
LT3334747T (en) | 2015-08-13 | 2023-12-27 | Amgen Inc. | Charged depth filtration of antigen-binding proteins |
KR20180054791A (en) * | 2015-09-28 | 2018-05-24 | 쑤저우 선카디아 바이오파마수티컬즈 컴퍼니 리미티드 | Stable anti-PD-1 antibody pharmaceutical preparations and its application in medicine |
CN105127166A (en) * | 2015-09-29 | 2015-12-09 | 中国华能集团清洁能源技术研究院有限公司 | Walking module and photovoltaic module cleaning device with same |
RS62035B1 (en) * | 2016-06-27 | 2021-07-30 | Morphosys Ag | Anti-cd19 antibody formulations |
BR112018014281A2 (en) * | 2016-11-15 | 2018-12-18 | H Lundbeck As | agents, uses and methods for the treatment of synucleinopathy |
BR112018016717A2 (en) | 2016-12-16 | 2018-12-26 | H Lundbeck As | agents, uses and methods |
US10364286B2 (en) | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
CN110506057B (en) | 2017-02-17 | 2023-09-29 | 百时美施贵宝公司 | ALPHA synuclein antibody and application thereof |
JP2021502955A (en) * | 2017-09-28 | 2021-02-04 | プロセナ・バイオサイエンシズ・リミテッド | Administration regimen for the treatment of synuclein disease |
US20190153102A1 (en) * | 2017-09-28 | 2019-05-23 | Prothena Biosciences Limited | Dosing regimes for treatment of synucleinopathies |
JP6831861B2 (en) | 2019-01-25 | 2021-02-17 | 株式会社Grin | Dental measuring instruments, measuring methods, and attachment instruments |
CR20210435A (en) | 2019-02-18 | 2021-09-20 | Lilly Co Eli | Therapeutic antibody formulation |
EP3786174A1 (en) * | 2019-08-27 | 2021-03-03 | Ichnos Sciences SA | Methods for antibody purification |
GB2587228B (en) * | 2019-09-20 | 2021-10-27 | Protein Ark Ltd | Biological sample purification apparatus, use of the same, and systems comprising the same |
WO2022020680A1 (en) | 2020-07-23 | 2022-01-27 | Othair Prothena Limited | Anti-abeta antibodies |
CN114516914B (en) * | 2020-11-19 | 2023-04-28 | 东莞市朋志生物科技有限公司 | Antibodies against N-terminal brain natriuretic peptide precursors, and reagents and kits for detecting N-terminal brain natriuretic peptide precursors |
KR20240055758A (en) * | 2021-09-16 | 2024-04-29 | 하. 룬드벡 아크티에셀스카브 | Compositions and methods for treating synucleinopathies |
Family Cites Families (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
IE64738B1 (en) | 1990-03-20 | 1995-09-06 | Akzo Nv | Stabilized gonadotropin containing preparations |
ES2206447T3 (en) | 1991-06-14 | 2004-05-16 | Genentech, Inc. | HUMANIZED ANTIBODY FOR HEREGULINE. |
US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
AU695129B2 (en) | 1995-02-06 | 1998-08-06 | Genetics Institute, Llc | Formulations for IL-12 |
DE19539493A1 (en) | 1995-10-24 | 1997-04-30 | Thomae Gmbh Dr K | Strong homologous promoter from hamster |
US5834597A (en) | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
US5888809A (en) | 1997-05-01 | 1999-03-30 | Icos Corporation | Hamster EF-1α transcriptional regulatory DNA |
SG142124A1 (en) | 1999-02-05 | 2008-05-28 | Samsung Electronics Co Ltd | Image texture retrieving method and apparatus thereof |
PT1355919E (en) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Molecules with extended half-lives, compositions and uses thereof |
AU2002368077B2 (en) | 2001-07-12 | 2010-03-04 | Jefferson Foote | Super humanized antibodies |
BR0309093A (en) | 2002-04-09 | 2005-02-09 | Flamel Tech Sa | Oral pharmaceutical formulation in aqueous microcapsule suspension allowing modified release of amoxicillin |
CA2485342A1 (en) | 2002-05-13 | 2004-05-13 | Alexion Pharmaceuticals, Inc. | Humanized antibodies against the venezuelan equine encephalitis virus |
US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
WO2008103472A2 (en) | 2007-02-23 | 2008-08-28 | Elan Pharmaceuticals, Inc. | Prevention and treatment of synucleinopathic and amyloidogenic disease |
TW200509968A (en) | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
US9034337B2 (en) | 2003-10-31 | 2015-05-19 | Prothena Biosciences Limited | Treatment and delay of outset of synucleinopathic and amyloidogenic disease |
US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
ES2293096T3 (en) | 2002-11-29 | 2008-03-16 | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG | NEW GENES OF NEOMYCINE PHOSPHOTRANSPHERASE AND PROCEDURE FOR THE SELECTION OF ELEVATED PRODUCTION RECOMBINATING CELLS. |
DK2335725T3 (en) | 2003-04-04 | 2017-01-23 | Genentech Inc | Highly concentrated antibody and protein formulations |
US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
DE10338531A1 (en) | 2003-08-19 | 2005-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Method for recloning production cells |
WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
EP1697741A4 (en) | 2003-12-04 | 2008-02-13 | Xencor Inc | Methods of generating variant proteins with increased host string content and compositions thereof |
JO3000B1 (en) | 2004-10-20 | 2016-09-05 | Genentech Inc | Antibody Formulations. |
DK1820022T3 (en) | 2004-11-10 | 2009-09-14 | Boehringer Ingelheim Pharma | Application of flow cytometric analysis to optimize cell bank strategies of CHO cells |
WO2007011907A2 (en) | 2005-07-19 | 2007-01-25 | University Of Rochester | Alpha-synuclein antibodies and methods related thereto |
AU2006329963B2 (en) * | 2005-12-06 | 2011-06-09 | Amgen Inc. | Polishing steps used in multi-step protein purification processes |
EP2046833B9 (en) | 2006-07-14 | 2014-02-19 | AC Immune S.A. | Humanized antibody against amyloid beta |
US20080124760A1 (en) | 2006-07-26 | 2008-05-29 | Barbara Enenkel | Regulatory Nucleic Acid Elements |
CA2678863A1 (en) | 2007-02-23 | 2008-08-28 | Schering Corporation | Engineered anti-il-23p19 antibodies |
US8147833B2 (en) * | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
EP2126093B1 (en) | 2007-03-02 | 2012-10-10 | Boehringer Ingelheim Pharma GmbH & Co. KG | Improvement of protein production |
RU2500686C2 (en) | 2007-03-22 | 2013-12-10 | Дженентек, Инк. | APOPTOTIC ANTIBODIES AGAINST IgE |
MX2009010179A (en) * | 2007-03-22 | 2010-03-15 | Imclone Llc | Stable antibody formulations. |
EP2031064A1 (en) | 2007-08-29 | 2009-03-04 | Boehringer Ingelheim Pharma GmbH & Co. KG | Method for increasing protein titres |
US9308257B2 (en) * | 2007-11-28 | 2016-04-12 | Medimmune, Llc | Protein formulation |
PT2234600E (en) | 2007-12-21 | 2014-09-25 | Hoffmann La Roche | Antibody formulation |
EP2730659A3 (en) | 2007-12-28 | 2016-01-13 | Prothena Biosciences Limited | Treatment and Prophylaxis of Amyloidosis |
LT2282758T (en) | 2008-04-29 | 2019-03-12 | Bioarctic Ab | Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
WO2009141239A1 (en) * | 2008-05-20 | 2009-11-26 | F. Hoffmann-La Roche Ag | A pharmaceutical formulation comprising an antibody against ox40l, uses thereof |
US20120276019A1 (en) | 2008-07-25 | 2012-11-01 | Diamedica Inc. | Tissue kallikrein for the treatment of parkinson's disease |
ES2544569T3 (en) | 2008-12-19 | 2015-09-01 | Biogen International Neuroscience Gmbh | Human anti-alpha-synuclein autoantibodies |
CN109172813B (en) | 2009-07-28 | 2022-09-02 | 武田药品工业株式会社 | Compositions and methods for treating gaucher disease |
AR078161A1 (en) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | VERY CONCENTRATED PHARMACEUTICAL FORMULATIONS OF AN ANTIBODY ANTI CD20. USE OF THE FORMULATION. TREATMENT METHOD |
EP2519537A4 (en) | 2009-12-29 | 2013-07-10 | Reddys Lab Ltd Dr | Purification of proteins |
EP2366714A1 (en) | 2010-03-03 | 2011-09-21 | Dr. Rentschler Holding GmbH & Co. KG | Naturally occuring autoantibodies against alpha-synuclein that inhibit the aggregation and cytotoxicity of alpha-synuclein |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
US9028830B2 (en) | 2010-04-08 | 2015-05-12 | JN Biosciences, LLC | Antibodies to CD122 |
TWI526161B (en) | 2010-06-10 | 2016-03-21 | 亞培公司 | Substantially clear nutritional liquids comprising calcium hmb and soluble protein |
ES2682078T3 (en) | 2010-06-11 | 2018-09-18 | Kyowa Hakko Kirin Co., Ltd. | Anti-TIM-3 antibody |
JP5886283B2 (en) | 2010-07-15 | 2016-03-16 | アドヘロン セラピューティクス,インコーポレイテッド | Humanized antibodies targeting the EC1 domain of cadherin-11 and related compositions and methods |
EP2627425A4 (en) * | 2010-10-11 | 2014-11-05 | Abbvie Inc | Processes for purification of proteins |
CA2825791A1 (en) | 2011-02-07 | 2012-08-16 | Neotope Biosciences Limited | Apoe immunotherapy |
WO2012160536A1 (en) | 2011-05-26 | 2012-11-29 | Dr Reddy's Laboratories Limited | Antibody purification |
CA2840224C (en) | 2011-06-22 | 2019-08-13 | The General Hospital Corporation | Treatment of proteinopathies |
EP2726098A1 (en) * | 2011-06-30 | 2014-05-07 | F.Hoffmann-La Roche Ag | Anti-c-met antibody formulations |
PE20191242A1 (en) * | 2011-10-25 | 2019-09-16 | Prothena Biosciences Ltd | ANTIBODY FORMULATIONS AND METHODS |
UA116194C2 (en) | 2011-10-28 | 2018-02-26 | Протена Біосаєнсиз Лімітед | ANTIBODY THAT SPECIFICALLY Binds to HUMAN ALPHA SYNUCLEIN |
KR20140084078A (en) | 2011-10-31 | 2014-07-04 | 제넨테크, 인크. | Antibody formulations |
ES2749457T3 (en) | 2012-01-27 | 2020-03-20 | Prothena Biosciences Ltd | Humanized antibodies that recognize alpha-synuclein |
US9216219B2 (en) * | 2012-06-12 | 2015-12-22 | Novartis Ag | Anti-BAFFR antibody formulation |
SI2890712T1 (en) | 2012-08-29 | 2019-08-30 | F. Hoffmann-La Roche Ag | Blood brain barrier shuttle |
US8925815B2 (en) | 2012-09-05 | 2015-01-06 | Symbol Technologies, Inc. | Checkout system for and method of preventing a customer-operated accessory reader facing a bagging area from imaging targets on products passed through a clerk-operated workstation to the bagging area |
UA118441C2 (en) | 2012-10-08 | 2019-01-25 | Протена Біосаєнсиз Лімітед | Antibodies recognizing alpha-synuclein |
US10513555B2 (en) | 2013-07-04 | 2019-12-24 | Prothena Biosciences Limited | Antibody formulations and methods |
US10562973B2 (en) | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
US10084674B2 (en) | 2015-09-09 | 2018-09-25 | International Business Machines Corporation | Virtual desktop operation and data continuity preservation |
-
2014
- 2014-07-02 US US14/322,797 patent/US10513555B2/en active Active
- 2014-07-03 ES ES14752412T patent/ES2704440T3/en active Active
- 2014-07-03 CU CUP2017000039A patent/CU20170039A7/en unknown
- 2014-07-03 CN CN201480047476.9A patent/CN105492019B/en active Active
- 2014-07-03 AU AU2014285719A patent/AU2014285719A1/en not_active Abandoned
- 2014-07-03 WO PCT/IB2014/062806 patent/WO2015001504A2/en active Application Filing
- 2014-07-03 RU RU2016103079A patent/RU2016103079A/en not_active Application Discontinuation
- 2014-07-03 KR KR1020167003163A patent/KR20160030247A/en not_active Application Discontinuation
- 2014-07-03 MX MX2016000201A patent/MX2016000201A/en unknown
- 2014-07-03 JP JP2016522950A patent/JP6404338B2/en active Active
- 2014-07-03 EP EP14752412.8A patent/EP3016677B1/en active Active
- 2014-07-03 EP EP18212531.0A patent/EP3524264A1/en active Pending
- 2014-07-03 PE PE2015002708A patent/PE20160868A1/en not_active Application Discontinuation
- 2014-07-03 SG SG11201510601TA patent/SG11201510601TA/en unknown
- 2014-07-03 CA CA2917097A patent/CA2917097C/en active Active
-
2015
- 2015-12-16 PH PH12015502788A patent/PH12015502788A1/en unknown
- 2015-12-31 CL CL2015003801A patent/CL2015003801A1/en unknown
- 2015-12-31 IL IL243425A patent/IL243425A0/en unknown
-
2016
- 2016-01-04 CU CUP2016000001A patent/CU20160001A7/en unknown
- 2016-10-12 HK HK16111756.3A patent/HK1223544A1/en unknown
-
2018
- 2018-09-12 JP JP2018170393A patent/JP6854266B2/en active Active
-
2019
- 2019-11-01 US US16/672,330 patent/US20200140534A1/en not_active Abandoned
-
2020
- 2020-10-23 JP JP2020177954A patent/JP2021020941A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN105492019B (en) | 2020-02-11 |
PH12015502788A1 (en) | 2016-03-21 |
MX2016000201A (en) | 2016-05-31 |
PE20160868A1 (en) | 2016-09-24 |
CA2917097A1 (en) | 2015-01-08 |
EP3016677A2 (en) | 2016-05-11 |
WO2015001504A2 (en) | 2015-01-08 |
JP2021020941A (en) | 2021-02-18 |
US20200140534A1 (en) | 2020-05-07 |
JP2019011339A (en) | 2019-01-24 |
CN105492019A (en) | 2016-04-13 |
HK1223544A1 (en) | 2017-08-04 |
EP3016677B1 (en) | 2018-12-19 |
JP6404338B2 (en) | 2018-10-10 |
AU2014285719A1 (en) | 2016-01-21 |
JP2016534052A (en) | 2016-11-04 |
RU2016103079A (en) | 2017-08-07 |
CU20170039A7 (en) | 2017-06-05 |
US10513555B2 (en) | 2019-12-24 |
WO2015001504A3 (en) | 2015-08-06 |
CA2917097C (en) | 2022-05-03 |
EP3524264A1 (en) | 2019-08-14 |
JP6854266B2 (en) | 2021-04-07 |
ES2704440T3 (en) | 2019-03-18 |
KR20160030247A (en) | 2016-03-16 |
CL2015003801A1 (en) | 2016-07-15 |
CU20160001A7 (en) | 2016-08-31 |
IL243425A0 (en) | 2016-03-31 |
US20150079074A1 (en) | 2015-03-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL261743B (en) | Anti-il-33 antibodies and uses thereof | |
HK1223544A1 (en) | Antibody formulations and methods | |
ZA202005525B (en) | Antibody formulations | |
HK1232243A1 (en) | Anti-b7-h5 antibodies and their uses -b7-h5 | |
IL261547B (en) | Anti-hepcidin antibodies and uses thereof | |
IL244712B (en) | Anti-pdl1 antibody formulations | |
IL245040B (en) | Anti-pdgfr-beta antibodies and uses thereof | |
IL243974B (en) | Anti-prlr antibodies and uses thereof | |
IL240517A0 (en) | Anti-b7-h4 antibodies and immunoconjugates | |
SG10201708143QA (en) | Anti-c10orf54 antibodies and uses thereof | |
SG11201509116VA (en) | Anti-tweakr antibodies and uses thereof |